MARKET

CRMD

CRMD

Cormedix
NASDAQ
4.980
+0.170
+3.53%
After Hours: 4.980 0 0.00% 16:49 06/01 EDT
OPEN
4.830
PREV CLOSE
4.810
HIGH
5.04
LOW
4.830
VOLUME
167.51K
TURNOVER
0
52 WEEK HIGH
8.03
52 WEEK LOW
2.645
MARKET CAP
225.98M
P/E (TTM)
-6.2768
1D
5D
1M
3M
1Y
5Y
JMP Securities Maintains CorMedix (CRMD) Market Outperform Recommendation
NASDAQ · 05/20 09:52
As CorMedix's DefenCath Moves Forward On Regulatory Path, Analyst Boosts Price Target
Benzinga · 05/19 18:09
Cormedix: Statement of changes in beneficial ownership of securities
Press release · 05/19 16:03
JMP Securities Maintains Market Outperform on Cormedix, Raises Price Target to $19
Benzinga · 05/19 10:06
--JMP Securities Adjusts Price Target on CorMedix to $19 From $16, Keeps Market Outperform Rating
--JMP Securities Adjusts Price Target on CorMedix to $19 From $16, Keeps Market Outperform Rating
MT Newswires · 05/19 09:37
JMP Securities Remains a Buy on Cormedix (CRMD)
TipRanks · 05/18 18:45
Cormedix: [Amend]Statement of changes in beneficial ownership of securities
Press release · 05/18 18:27
Needham Reiterates CorMedix (CRMD) Buy Recommendation
NASDAQ · 05/17 06:48
More
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on developing its product DefenCath, which is an antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic emodialysis. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL intended for the reduction of catheter-related infections and thrombosis in patients requiring central venous catheters CVCs in clinical settings, such as hemodialysis, total parenteral nutrition and oncology. In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.

Webull offers kinds of CorMedix Inc. stock information, including NASDAQ:CRMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRMD stock methods without spending real money on the virtual paper trading platform.